# Modelling of COVID-19 epidemic and INTERVENTIONS WITHIN IDP CAMPS

Dr. Eduard Campillo-Funollet, PhD, Univ. of Sussex (UK) JORDAN KLEIN, MPH, PRINCETON UNIV. (USA) Dr. Alberto Pascual-García, PhD, ETH-Zürich (Switzerland) Dr. Jennifer Villers, PhD, Princeton Univ. (USA) CHAMSY SARKIS, PAX SYRIANA FOUNDATION

July  $16^{\text{th}}$ , 2020





### MODEL PRELIMINARIES

# Between December 2019 and March 2020, 1M new IDP → Informal settlements HIGH DENSITY and no management

~700 camps with 600 person per camp on average (log-normal)

80% family-sized tents (~7 people)

Most of the informal camps have no management.

Source: UN- REACH REPORT, JANUARY-MARCH 2020

#### Between December 2019 and March 2020, 1M new IDP → Informal settlements

#### **HIGH DENSITY and no management**

~700 camps with 600 person per camp on average (log-normal)

80% family-sized tents (~7 people)

Most of the informal camps have no management.

#### **NO POSSIBLE lockdown**

50% no access to electricity

External water, with 25% not have enough drinking water

External latrines, and 10% households have 1 member disable/elderly.

360% drop of Syrian pound (no access to goods) → high motility to work

Source: UN- REACH REPORT, JANUARY-MARCH 2020

#### Between December 2019 and March 2020, 1M new IDP → Informal settlements

#### **HIGH DENSITY and no management**

~700 camps with 600 person per camp on average (log-normal)

80% family-sized tents (~7 people)

Most of the informal camps have no management.

#### **NO POSSIBLE lockdown**

50% no access to electricity

External water, with 25% not have enough drinking water

External letrines, and 10% households have 1 member disable/elderly.

360% drop of Syrian pound (no access to goods) → high motility to work

#### **HIGH comorbidity**

10% population has chronic diseases, 17% of them have no access to medicines.

Source: UN- REACH REPORT, JANUARY-MARCH 2020

#### AIM

#### **IDENTIFY FEASIBLE INTERVENTIONS:**

- Immediate applicability
- No need of complex technical infrastructure (e.g. testing, protection)
  - Cost: as low as possible

### Outlook


#### Modelling


- Compartment models.
- Age-structured.
- Deterministic and stochastic simulations.
- Parameters estimated for IDPCs.
- Different camp sizes.
- ~70 different interventions modelled
- ~100K different simulations.

#### Strategies


- Self-distancing
- Shielding, lockdown
- Isolation
- Combined strategies

### THE MODEL





# Hospitalization capacity



# Hospitalization capacity







Figure 6 Scenario One predicted severe cases

The health system in NW Syria would be unable to cope by the beginning of week 8; as such, severe cases could become critical and mortality could increase







### Population Pyramid in NW of Syria




#### Population Pyramid in NW of Syria



#### Population Pyramid in NW of Syria








| Parameter                 | Description                               | Value                                  | Distribution | Reference |
|---------------------------|---|--|--------------|-----------|
| $1/\delta_E + 1/\delta_P$ | Duration of incubation period             | 5.2 (95% CI:                           | Lognormal    | [1]       |
|                           | in days                                   | 4.1-7.0)                               |              |           |
| $1/\delta_E$              | Duration of latency in days               | $1/\delta_E + 1/\delta_P - 1/\delta_P$ |              | [2]       |
| $1/\delta_P$              | Duration of preclinical                   | 2.3 (95% CI:                           | Gompertz     | [2]       |
|                           | infectiousness in days                    | 0.8 - 3.0)                             |              |           |
| $1/\gamma_A = 1/\gamma_I$ | Duration of clinical $(1/\gamma_I)$ and   | 7                                      |              | [2, 3]    |
|                           | subclinical $(1/\gamma_A)$ infectiousness |  |              |           |
|                           | in days                                   |  |              |           |
| $1/\eta$                  | Delay from symptoms onset to              | 7 (IQR: 4-8)                           | Gamma        | [4]       |
|                           | hospitalization in days                   |  |              |           |
| $1/\alpha$                | Delay from symptoms onset to              | 10 (IQR: 6-12)                         | Gamma        | [4]       |
|                           | ICU (here death) in days                  |  |              |           |
| $1/\gamma_H$              | Delay from hospitalization to             | 10 (IQR: 7-14)                         | Gamma        | [4]       |
|                           | recovery in days                          |  |              |           |
| f                         | Fraction of infected people who           | 0.84 (95% CI:                          | Binomial     | [5]       |
|                           | develop symptoms                          | 0.8 - 0.88)                            |              |           |
| $h_i$                     | Fraction of symptomatic                   | Age- and                               |              | [6, 7]    |
|                           | people requiring hospitalization          | comorbidity-                           |              |           |
|                           | but not ICU                               | dependent                              |              |           |
| $g_i$                     | Fraction of symptomatic                   | Age- and                               |              | [6, 7]    |
|                           | people requiring ICU                      | comorbidity-                           |              |           |
|                           |   | dependent                              |              |           |

| Parameter                 | Description                               | Value                                  | Distribution | Reference |
|---------------------------|---|--|--------------|-----------|
| $1/\delta_E + 1/\delta_P$ | Duration of incubation period             | 5.2 (95% CI:                           | Lognormal    | [1]       |
|                           | in days                                   | 4.1-7.0)                               |              |           |
| $1/\delta_E$              | Duration of latency in days               | $1/\delta_E + 1/\delta_P - 1/\delta_P$ |              | [2]       |
| $1/\delta_P$              | Duration of preclinical                   | 2.3 (95% CI:                           | Gompertz     | [2]       |
|                           | infectiousness in days                    | 0.8 - 3.0)                             |              |           |
| $1/\gamma_A = 1/\gamma_I$ | Duration of clinical $(1/\gamma_I)$ and   | 7                                      |              | [2, 3]    |
|                           | subclinical $(1/\gamma_A)$ infectiousness |  |              |           |
|                           | in days                                   |  |              |           |
| $1/\eta$                  | Delay from symptoms onset to              | 7 (IQR: 4-8)                           | Gamma        | [4]       |
|                           | hospitalization in days                   |  |              |           |
| $1/\alpha$                | Delay from symptoms onset to              | 10 (IQR: 6-12)                         | Gamma        | [4]       |
|                           | ICU (here death) in days                  |  |              |           |
| $1/\gamma_H$              | Delay from hospitalization to             | 10 (IQR: 7-14)                         | Gamma        | [4]       |
|                           | recovery in days                          |  |              |           |
| f                         | Fraction of infected people who           | 0.84 (95% CI:                          | Binomial     | [5]       |
|                           | develop symptoms                          | 0.8 - 0.88)                            |              |           |
| $h_i$                     | Fraction of symptomatic                   | Age- and                               |              | [6, 7]    |
|                           | people requiring hospitalization          | comorbidity-                           |              |           |
|                           | but not ICU                               | dependent                              |              |           |
| $g_i$                     | Fraction of symptomatic                   | Age- and                               |              | [6, 7]    |
|                           | people requiring ICU                      | comorbidity-                           |              |           |
|                           |   | dependent                              |              |           |

| Parameter                 | Description                               | Value                                  | Distribution   | Reference |
|---------------------------|---|--|----------------|-----------|
| $1/\delta_E + 1/\delta_P$ | Duration of incubation period             | 5.2 (95% CI:                           | Lognormal      | [1]       |
|                           | in days                                   | 4.1-7.0)                               |                |           |
| $1/\delta_E$              | Duration of latency in days               | $1/\delta_E + 1/\delta_P - 1/\delta_P$ |                | [2]       |
| $1/\delta_P$              | Duration of preclinical                   | 2.3 (95% CI:                           | Gompertz       | [2]       |
|                           | infectiousness in days                    | 0.8 - 3.0)                             |                |           |
| $1/\gamma_A = 1/\gamma_I$ | Duration of clinical $(1/\gamma_I)$ and   | 7                                      |                | [2,  3]   |
|                           | subclinical $(1/\gamma_A)$ infectiousness |  |                |           |
|                           | in days                                   |  |                |           |
| $1/\eta$                  | Delay from symptoms onset to              | 7 (IQR: 4-8)                           | Gamma          | [4]       |
|                           | hospitalization in days                   |  |                |           |
| $1/\alpha$                | Delay from symptoms onset to              | 10 (IQR: 6-12)                         | Gamma          | [4]       |
|                           | ICU (here death) in days                  |  |                |           |
| $1/\gamma_H$              | Delay from hospitalization to             | 10 (IQR: 7-14)                         | Gamma          | [4]       |
|                           | recovery in days                          |  |                |           |
| f                         | Fraction of infected people who           | 0.84 (95% CI:                          | Binomial       | [5]       |
|                           | develop symptoms                          | 0.8 - 0.88)                            |                |           |
| $h_i$                     | Fraction of symptomatic                   | Age- and                               | Values mapped  | [6, 7]    |
|                           | people requiring hospitalization          | comorbidity-                           | to individuals |           |
|                           | but not ICU                               | dependent                              | 10 years older |           |
| $g_i$                     | Fraction of symptomatic                   | Age- and                               | Values mapped  | [6, 7]    |
|                           | people requiring ICU                      | comorbidity-                           | to individuals |           |
|                           |   | dependent                              | 10 years older |           |







$$\lambda_i = \sum_{j=1}^n \beta_{ij} \frac{P_j + A_j + I_j + H_j}{N_j}$$


With: 
$$eta_{ij} = au C_{ij}$$


T is the probability of infection if there is a contact C is the number of contacts between population classes i and j


$$\lambda_i = \sum_{j=1}^n \beta_{ij} \frac{P_j + A_j + I_j + H_j}{N_j}$$

With:  $\beta_{ij} = \tau C_{ij}$ 

T is the probability of infection if there is a contact
C is the number of contacts between population classes i and j







### THE RESULTS

### Description

 Reduction of contacts between individuals.

### **Key-points**

- Simple and rapid implementation.
- Educational-based, long-term benefit
- Starting investment then mouth-to-word

### Description

 Reduction of contacts between individuals.

| Population class | Null<br>model | Reduction 20% | Reduction 50% |
|------------------|---------------|---------------|---------------|
| Kids             | 25            | 20            | 12.5          |
| Adults           | 15            | 11            | 7.5           |
| Elderly          | 10            | 8             | 5             |

### **Key-points**

- Simple and rapid implementation.
- Educational-based, long-term benefit
- Starting investment then mouth-to-word


### Description


 Reduction of contacts between individuals.


| Population class | Null<br>model | Reduction 20% | Reduction 50% |
|------------------|---------------|---------------|---------------|
| Kids             | 25            | 20            | 12.5          |
| Adults           | 15            | 11            | 7.5           |
| Elderly          | 10            | 8             | 5             |


### **Key-points**


- Simple and rapid implementation.
- Educational-based, long-term benefit
- Starting investment then mouth-to-word











Up to 40% reduction in the the death tolls

Up to 40% delay in the peak of infected population

## Strategy 2: Shielding and Lockdown

### Description

- Shield of <u>vulnerable</u> population.
- Similar conditions in terms of tents occupancy and distance between tents were considered.
- Vulnerable:
  - Elderly.
  - People with co-morbidities.
  - · Carers/family.
- Lockdown when <u>first symptom</u> is detected.

80% of the population


Neutral zone


20% of the population


- 45 kids (0-18 yo)
- 35 adults
- Meetings between orange and green in « neutral zone »
   (open tent), no more than 4 people at a time (mixed orange/green). No physical contact (mask and gloves, 1.5 meter distance).

For a total population of 100 persons


- 5 elderly (60+)
- 10 middle-aged NCD affected (mainly people 40-60 years old)
- 5 kids (<13 yrs)
- Intra-green zone carers are among the 10 non-elderly NCD
- No unprotected contact with orange zone or external world
- In average, meeting in neutral zone once per week (2 to 10 contacts per week with orange zone)









### Strategy 2: Shielding only




### Strategy 2: Shielding only







### Strategy 2: Shielding only




#### Lockdown of the "green" zone after first symptomatic case




#### Lockdown of the "green" zone after first symptomatic case




### Strategy 2: Shielding and Lockdown



# Strategy 3: Isolation



### Strategy 3: Isolation




Assumptions:

- Symptomatic people are <u>isolated after they</u> recognize their symptoms (12-48h),.
- The fate of the patients is not better nor worse than if staying in the camp → <u>Discards isolating</u> people together without testing.


Isolation

• The model includes the presence of <u>"carers"</u> which cannot be neglected, even less without an adequate protection.


### Model




### Model





# Strategy 3: Isolation





# Strategy 3: Isolation

















### Conclusions

- Simple interventions can reduce the probability of outbreak and death tolls.
- Setting safety areas under appropriate conditions have an overall positive effect. An increase in the probability of outbreak can be mitigated by self-distancing.
- **Isolation** brings the stronger reduction in death tolls. However, it may accelerate the spread of the virus among the vulnerable population.
- The combination of interventions are very effective against the spread of the virus and its potential impact in the population.

#### Future work

- Determine the optimal population fraction that should be shielded (simulations done, analysis required).
- What can we expect in terms of herd immunity depending on the intervention, and estimate accurate times for e.g. lockdown.
- More accurate extrapolation of the spread of the infection at a regional scale.
- More realistic modelling of some interventions, e.g. introduction of carers if isolation.

#### Acknowledgements

#### Contributors:

- Jordan Klein (Princeton University)
- Jennifer Villers (Princeton University)
- Eduard Campillo-Funollet, University of Sussex
- Judith Bouman (ETH-Zürich)
- Chamsy Sarkis (Pax Syriana Foundation)

#### Thanks for useful discussions:

- Burcu Tepekule (ETH-Zürich)
- Juan Poyatos (Spanish Research Council)